Veterans lobby for MDMA approval for PTSD treatment

Veterans are lobbying for FDA approval of MDMA-assisted therapy for PTSD, with a decision expected by August 11. In June, an FDA advisory committee overwhelmingly rejected the drug's evidence, citing research flaws. Two phase 3 trials showed over 70% of participants no longer met PTSD criteria after treatment. Controversies surrounding trial conduct and safety concerns complicate the approval process, with public advocacy playing a significant role.